Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 7:55 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1297–1320 of 1,823 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Media Clear all

Conditions: Test Performance When Distracted or Not
Interventions: TV; Other
Lead sponsor: Seattle Children's Hospital; Other
Eligibility: 10 Years to 15 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Gut Microbiome, Neurocognitive Correlates of Eating Habits, Infant Growth
Interventions: Daily avocado; Other
Lead sponsor: Arizona State University; Other
Eligibility: 3 Months to 6 Months
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Migraine
Interventions: Stage 1: Naltrexone/Acetaminophen, Stage 1: Naltrexone, Stage 1: Acetaminophen, Stage1: Placebo, Stage 2: Naltrxone/Acetaminophen high dose, Stage 2: Naltrexone/Acetaminophen medium dose, Stage 2: Naltrxone/Acetaminophen low dose, Stage 2: Placebo; Drug
Lead sponsor: Allodynic Therapeutics, Inc; Industry
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: North Miami, Florida

Conditions: Acute Pain, Postoperative
Interventions: LTG-001 High Dose, LTG-001 Mid Dose, LTG-001 Low Dose, Placebo, Suzetrigine; Drug · Other
Lead sponsor: Latigo Biotherapeutics; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Psoriatic Arthritis
Interventions: NDI-034858, Placebo; Drug · Other
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 305 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 23
States / cities: Palm Desert, California • Upland, California • Hollywood, Florida + 19 more

Conditions: Neoplasms
Interventions: BI 754091; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 7
States / cities: Sarasota, Florida • Harvey, Illinois • Detroit, Michigan + 4 more

Conditions: Otitis Media
Interventions: Prescription Fill Status; Behavioral
Lead sponsor: Yale University; Other
Eligibility: 6 Months to 12 Years
Enrollment: 240 participants
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: CVD, Sedentary Behavior
Interventions: Hoosier Sport Re-Social; Behavioral
Lead sponsor: Indiana University; Other
Eligibility: 12 Years to 14 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 2
States / cities: Bloomington, Indiana • Lyons, Indiana

Conditions: Communication Research
Interventions: Exposure to conflicting health information, No exposure to conflicting health information; Other
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 6,046 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Osteoarthritis of the Hip
Interventions: Not listed
Lead sponsor: Rothman Institute Orthopaedics; Other
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Schizophrenia
Interventions: Samidorphan (Low Dose), Samidorphan (Medium Dose), Samidorphan (High Dose), Placebo, Olanzapine; Drug
Lead sponsor: Alkermes, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 347 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 50
States / cities: Little Rock, Arkansas • Anaheim, California • Costa Mesa, California + 43 more

Conditions: Pyruvate Kinase Deficiency, Glucose 6 Phosphate Dehydrogenase Deficiency
Interventions: Vitamin C; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Caries,Dental
Interventions: Comparison School Group, Intervention School Group; Behavioral
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 5 Years to 9 Years
Enrollment: 1,084 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Elbow Force
Interventions: Motion capture participant; Behavioral
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 16 Years to 40 Years · Male only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hematopoietic and Lymphoid System Neoplasm, Malignant Solid Neoplasm
Interventions: Biospecimen Collection, Genetic Testing for Cancer Risk, Liquid Biopsy, Magnetic Resonance Imaging of the Whole Body without Contrast, Survey Administration; Procedure · Genetic · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Duarte, California

Conditions: Healthy
Interventions: Pregabalin controlled release, 330 mg, low-fat, Pregabalin controlled release, 330 mg, medium-fat, Pregabalin controlled release, 330 mg, high-fat, Pregabalin immediate release, 300 mg; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Electronic Cigarette Use
Interventions: Social Media Use Reduction; Behavioral
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years to 25 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Substance-Related Disorders, Drug Addiction, Substance Abuse
Interventions: Home-Based Intervention, Educational Group; Behavioral
Lead sponsor: Treatment Research Institute; Other
Eligibility: 12 Years to 19 Years
Enrollment: 286 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Cancer Survivors, Exercise, Sedentary Behavior
Interventions: 12-Week Home Exercise Group, Education Comparison Group; Behavioral
Lead sponsor: University of Illinois at Urbana-Champaign; Other
Eligibility: 30 Years to 75 Years
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Urbana, Illinois

Conditions: HIV Infections, HIV Wasting Syndrome
Interventions: Multivitamin and mineral supplements, Peptamen, NuBasics; Dietary Supplement
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 536 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 1998
U.S. locations: 17
States / cities: San Francisco, California • Denver, Colorado • Washington D.C., District of Columbia + 11 more

Conditions: Medulloblastoma
Interventions: Surgical resection, Ommaya/VPS, Methotrexate, Cisplatin, Vincristine, Cyclophosphamide, Carboplatin, Topotecan, Etoposide, Pegfilgrastim, Filgrastim, Irradiation, Educational and Media Intervention, SOC, Educational and Media Intervention; Procedure · Drug · Radiation + 1 more
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 59 Months
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2035
U.S. locations: 10
States / cities: Palo Alto, California • Orlando, Florida • Tampa, Florida + 7 more

Conditions: Allogeneic Hematopoietic Cell Transplantation
Interventions: Alemtuzumab; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: Not listed
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Teen Pregnancy Prevention
Interventions: Unstained, Like; Behavioral
Lead sponsor: The Policy & Research Group; Other
Eligibility: 14 Years to 22 Years
Enrollment: 1,500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Malaria
Interventions: Sanaria™ PfSPZ Vaccine, Chloroquine; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Search by objective public record fields.

Media Background and Test Performance

Early Avocado Exposure on Development and the Gut Microbiome in American Hispanic Infants

Single-Site Study of Naltrexone/Acetaminophen for the Acute Treatment of Migraine: A Phase 2 Randomized Trial

This is a Study Evaluating the Efficacy and Safety of LTG-001 for Acute Pain After Surgical Removal of Impacted Third Molars

A Study to Evaluate the Efficacy, Safety, and Tolerability of NDI-034858 in Participants With Active Psoriatic Arthritis

A Trial to Find and Investigate a Safe Dose of a New Substance (BI 754091) for Patients With Solid Tumours

Wait and See Antibiotic Prescription for Acute Otitis Media: A Randomized Controlled Trial

Hoosier Sport Re-Social: A Biobehavioral Intervention in Rural Indiana

Effects of Prior Exposure to Conflicting Health Information on Responses to Subsequent Unrelated Health Messages

Medium and Long Term Outcome of Total Hip Arthroplasty Using Accolade TMZF Femoral Stem

A Study of ALKS 3831 in Adults With Schizophrenia

High-Dose Vitamin C in G6PDA and Pyruvate Kinase Deficiency: A Safety Study

CATCH Healthy Smiles:An Elementary School Oral Health Intervention Trial

Motion Capture: Baseball Swing

Analysis of Whole Body Magnetic Resonance Imaging and Liquid Biopsy for Early Detection of Cancer in Patients With a Strong Family History of Cancer

An Investigation Of The Absorption And Pharmacokinetics Of A Single Dose Of A Controlled Release (CR) Pregabalin Tablet Following A Low, Medium, And High-Fat Evening Meal As Compared To A Single Dose Of The Immediate Release (IR) Pregabalin Capsule In Healthy Volunteers

Effects of Social Media Use on Young Adults' E-Cigarette Use

Home-Based Program to Help Parents of Drug Abusing Adolescents

Feasibility of a Novel, Theory Based Physical Activity Intervention Among Adult Cancer Survivors

A Comparison of Two Caloric Supplements in the Prevention of Weight Loss in Patients With AIDS Who Take Daily Multivitamin and Mineral Supplements

Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma

Precision Alemtuzumab Dosing for Allogeneic Hematopoietic Cell Transplantation

Evaluation of Unstained

Sanaria™ PfSPZ Challenge Vaccine